Wei Cao

Algemeen Directeur bij GRACELL BIOTECHNOLOGIES INC.

68 jaar

Health Technology

Consumer Services

Health Services

Profiel

Wei Cao is the founder of Gracell Biotechnologies (Shanghai) Co., Ltd. (founded in 2017) and Gracell Biotechnologies, Inc. (founded in 2017).
He is currently the Chief Executive Officer at Gracell Biotechnologies (HK) Ltd., Gracell Biopharmaceuticals, Inc., Suzhou Gracell Biotechnologies Co., Ltd., and Zephyrm Bioscience Ltd. (as an Independent Non-Executive Director starting in 2024).
Dr. Cao previously worked as a Director at AbelZeta Pharma, Inc. from 2010 to 2016 and as the President, Chief Operating Officer & Director at Cellular Biomedicine Group Ltd. from 2010 to 2013.
He holds a doctorate degree from Medical College of Virginia and Harvard Medical School, and an undergraduate degree from Zhongshan Hospital Fudan University.

Actieve functies van Wei Cao

Bedrijven	Functie	Begin
GRACELL BIOTECHNOLOGIES INC.	Algemeen Directeur	01-05-2017
Gracell Biotechnologies (Shanghai) Co., Ltd. Gracell Biotechnologies (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology Operates a clinical-stage biopharmaceutical company which discovers and develops cellular therapeutics for the patients suffering with cancer	Oprichter	21-05-2017
Gracell Biotechnologies (HK) Ltd.	Algemeen Directeur	-
Gracell Biopharmaceuticals, Inc. Gracell Biopharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Part of AstraZeneca PLC, Gracell Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in cell therapies for cancer and autoimmune diseases. The company is based in Dover, DE. The company develops next-generation CAR-T therapies that address challenges of conventional treatments, such as long manufacturing times, immune rejection, and limited efficacy against solid tumors. Its proprietary technology platforms include FasTCAR™, which enables rapid, next-day manufacturing of autologous CAR-T cells; TruUCAR™, an off-the-shelf allogeneic CAR-T platform using gene editing to reduce graft-versus-host disease and immune rejection; and SMART CART™, designed to overcome barriers in solid tumor treatment. Gracell advances a pipeline of dual-targeted CAR-T candidates, such as GC012F targeting BCMA and CD19, currently in clinical trials for multiple myeloma and refractory systemic lupus erythematosus. The company’s manufacturing capabilities include fully closed systems and collaborations to ensure high-quality, scalable production. The CEO of the company is Wei Cao.	Algemeen Directeur	-
Suzhou Gracell Biotechnologies Co., Ltd. Suzhou Gracell Biotechnologies Co., Ltd. Pharmaceuticals: MajorHealth Technology Manufactures cancer cellular medicines	Algemeen Directeur	-

Alle actieve functies van Wei Cao

Eerdere bekende functies van Wei Cao

Bedrijven	Functie	Einde
CELLULAR BIOMEDICINE GROUP, INC.	Algemeen Directeur	06-02-2016
Cellular Biomedicine Group Ltd.	President	01-02-2013

Ervaring van Wei Cao in detail bekijken

Opleiding van Wei Cao

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Ervaring van Wei Cao in detail bekijken

Connecties

Eerstegraads connecties

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Persoonlijk netwerk weergeven

Verwante bedrijven

Bedrijven in privébezit	10
Medical College of Virginia Medical College of Virginia Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Harvard Medical School Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Zhongshan Hospital Fudan University Zhongshan Hospital Fudan University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
AbelZeta Pharma, Inc. AbelZeta Pharma, Inc. BiotechnologyHealth Technology Develops cell therapies to cure cancer and inflammatory & immunological diseases	Health Technology
Cellular Biomedicine Group Ltd.
Gracell Biotechnologies (Shanghai) Co., Ltd. Gracell Biotechnologies (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology Operates a clinical-stage biopharmaceutical company which discovers and develops cellular therapeutics for the patients suffering with cancer	Health Technology
Gracell Biotechnologies, Inc. Gracell Biotechnologies, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops cell and gene therapy for the treatment of cancer and autoimmune diseases	Health Technology
Gracell Biotechnologies (HK) Ltd.
Gracell Biopharmaceuticals, Inc. Gracell Biopharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Part of AstraZeneca PLC, Gracell Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in cell therapies for cancer and autoimmune diseases. The company is based in Dover, DE. The company develops next-generation CAR-T therapies that address challenges of conventional treatments, such as long manufacturing times, immune rejection, and limited efficacy against solid tumors. Its proprietary technology platforms include FasTCAR™, which enables rapid, next-day manufacturing of autologous CAR-T cells; TruUCAR™, an off-the-shelf allogeneic CAR-T platform using gene editing to reduce graft-versus-host disease and immune rejection; and SMART CART™, designed to overcome barriers in solid tumor treatment. Gracell advances a pipeline of dual-targeted CAR-T candidates, such as GC012F targeting BCMA and CD19, currently in clinical trials for multiple myeloma and refractory systemic lupus erythematosus. The company’s manufacturing capabilities include fully closed systems and collaborations to ensure high-quality, scalable production. The CEO of the company is Wei Cao.	Health Services
Suzhou Gracell Biotechnologies Co., Ltd. Suzhou Gracell Biotechnologies Co., Ltd. Pharmaceuticals: MajorHealth Technology Manufactures cancer cellular medicines	Health Technology